JP2010525805A5 - - Google Patents

Download PDF

Info

Publication number
JP2010525805A5
JP2010525805A5 JP2010505002A JP2010505002A JP2010525805A5 JP 2010525805 A5 JP2010525805 A5 JP 2010525805A5 JP 2010505002 A JP2010505002 A JP 2010505002A JP 2010505002 A JP2010505002 A JP 2010505002A JP 2010525805 A5 JP2010525805 A5 JP 2010525805A5
Authority
JP
Japan
Prior art keywords
use according
nucleic acid
acid construct
promoter
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010505002A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010525805A (ja
Filing date
Publication date
Priority claimed from US11/790,992 external-priority patent/US20070286845A1/en
Application filed filed Critical
Publication of JP2010525805A publication Critical patent/JP2010525805A/ja
Publication of JP2010525805A5 publication Critical patent/JP2010525805A5/ja
Pending legal-status Critical Current

Links

JP2010505002A 2007-04-30 2008-04-27 内皮細胞特異性を示すプロモーター及びそのプロモーターを使って血管形成を制御する方法 Pending JP2010525805A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/790,992 US20070286845A1 (en) 2000-11-17 2007-04-30 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
PCT/IL2008/000543 WO2008132729A2 (en) 2007-04-30 2008-04-27 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Publications (2)

Publication Number Publication Date
JP2010525805A JP2010525805A (ja) 2010-07-29
JP2010525805A5 true JP2010525805A5 (enExample) 2011-05-26

Family

ID=38895566

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010505002A Pending JP2010525805A (ja) 2007-04-30 2008-04-27 内皮細胞特異性を示すプロモーター及びそのプロモーターを使って血管形成を制御する方法

Country Status (11)

Country Link
US (2) US20070286845A1 (enExample)
EP (1) EP2152317A4 (enExample)
JP (1) JP2010525805A (enExample)
KR (1) KR101525548B1 (enExample)
CN (2) CN103276015A (enExample)
AU (1) AU2008243817B2 (enExample)
CA (1) CA2685394A1 (enExample)
MX (1) MX2009011750A (enExample)
NZ (1) NZ581511A (enExample)
WO (1) WO2008132729A2 (enExample)
ZA (1) ZA200908331B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
EP1436313B1 (en) * 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
EP2310507A4 (en) * 2008-07-08 2013-03-20 David Gladstone Inst METHOD AND COMPOSITIONS FOR ANGIOGENIC MODULATION
MX338931B (es) 2010-01-05 2016-05-06 Vascular Biogenics Ltd Composiciones y metodo para tratar gliobastoma (gbm).
MX342641B (es) * 2010-01-05 2016-10-07 Vascular Biogenics Ltd Metodos para uso de un agente adenoviral anti-angiogenico especifico.
US20130052165A1 (en) * 2010-01-12 2013-02-28 Livnat Bangio Methods of Producing Adenovirus Vectors and Viral Preparations Generated Thereby
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells
CN103339262A (zh) * 2010-10-28 2013-10-02 弗吉尼亚联邦大学 具有治疗作用的癌症成像：治疗诊断学
EP2675901B1 (en) 2011-02-14 2018-05-30 Revivicor, Inc. Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
KR101989171B1 (ko) 2012-10-17 2019-06-14 바스큘라 바이오제닉스 리미티드 아데노바이러스를 사용하는 치료 방법
US9682154B2 (en) 2013-02-04 2017-06-20 Vascular Biogenics Ltd. Methods of inducing responsiveness to anti-angiogenic agent
CN107630004B (zh) 2017-09-01 2021-01-15 康希诺生物股份公司 降低可复制性腺病毒产生的细胞株及构建方法和应用
EP3697451A1 (en) 2017-10-20 2020-08-26 Vascular Biogenics Ltd. Diagnostic methods for anti-angiogenic agent therapy
JP2022524321A (ja) 2019-03-13 2022-05-02 バスキュラー バイオジェニックス リミテッド 抗腫瘍療法の方法
AU2020271998A1 (en) 2019-04-12 2021-09-30 Vascular Biogenics Ltd. Methods of anti-tumor therapy
CN110714028B (zh) * 2019-11-04 2021-08-31 中国人民解放军第四军医大学 可控性上调Ang-(1-7)靶向性防治低氧性肺动脉高压的表达载体
CN114457003A (zh) 2020-11-10 2022-05-10 维思尔治疗有限公司 预调节血管细胞用于转导的方法、转导方法和保存转导的细胞的方法
CN118434281A (zh) * 2021-09-20 2024-08-02 雷维维科公司 用于异种移植的包含十个基因修饰的多转基因猪
FR3158516A1 (fr) * 2024-01-23 2025-07-25 Asfalia Biologics Production de vecteurs toxiques

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US207985A (en) * 1878-09-10 Improvement in grain-separators
US4866042A (en) * 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
US5464764A (en) * 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6337209B1 (en) * 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
CA2108144A1 (en) * 1991-03-06 1992-09-07 Jack A. Roth Methods and compositions for the selective inhibition of gene expression
US5635385A (en) * 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6579697B1 (en) * 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
US8715645B2 (en) * 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US5747340A (en) * 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
US5906827A (en) * 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5734039A (en) * 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5712149A (en) * 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6100242A (en) * 1995-02-28 2000-08-08 The Regents Of The University Of California Gene therapies for enhancing cardiac function
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
JP2001503273A (ja) * 1996-11-08 2001-03-13 オクラホマ メディカル リサーチ ファウンデーション Ｅｐｃｒ制御エレメントにより調節される内皮特異的発現
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
US6206917B1 (en) * 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
ES2320603T3 (es) * 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
EP0909532A1 (en) * 1997-10-16 1999-04-21 Development Center For Biotechnology Environmentally compatible porous material comprising beneficial nematodes and its preparation
US6183737B1 (en) * 1997-10-30 2001-02-06 The General Hospital Corporation Bonding of cartilage pieces using isolated chondrocytes and a biological gel
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6180355B1 (en) * 1998-05-07 2001-01-30 University Of Maryland, Baltimore Method for diagnosing and treating chronic pelvic pain syndrome
US6239151B1 (en) * 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6576265B1 (en) * 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6376244B1 (en) * 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6479064B1 (en) * 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6265216B1 (en) * 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6866864B2 (en) * 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
US6652583B2 (en) * 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
US7067649B2 (en) * 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
ES2338529T3 (es) * 2000-11-17 2010-05-10 Vascular Biogenics Ltd. Prometores que exiben especificidad por celulas endoteliales y metodos para su utilizacion.
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
EP1207205A1 (en) * 2000-11-20 2002-05-22 Crucell Holland B.V. Adenoviral replicons
US6438802B1 (en) * 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
EP1436313B1 (en) * 2001-10-19 2010-09-22 Vascular Biogenics Ltd. Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulation of angiogenesis and anticancer therapy
US9738907B2 (en) * 2002-02-01 2017-08-22 Oxford Biomedica (Uk) Limited Viral vector
AU2003244347A1 (en) * 2002-02-04 2003-09-02 Takeda Chemical Industries, Ltd. Angiogenesis inhibitors
CN1424401A (zh) * 2003-01-06 2003-06-18 李川源 有条件复制型腺病毒及其构建方法和用途

Similar Documents

Publication Publication Date Title
CN108546717A (zh) 反义lncRNA介导顺式调控抑制靶基因表达的方法
JP2012010710A5 (enExample)
US8916378B2 (en) Polynucleotide constructs, pharmaceutical compositions and methods for targeted downregulations of angiogenesis and anticancer therapy
García-Moruja et al. Functional characterization of SDF-1 proximal promoter
JP2018509154A5 (enExample)
JP2010259439A5 (enExample)
JP2016027802A (ja) 肝特異的核酸調節要素ならびにその方法および用途
CN103981155B (zh) 靶向肝癌溶瘤腺病毒的构建法和应用
Cherian et al. An activating mutation of interferon regulatory factor 4 (IRF4) in adult T-cell leukemia
Cao et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter
JP2003528604A5 (enExample)
Coupeau et al. Kinetic expression analysis of the cluster mdv1-mir-M9–M4, genes meq and vIL-8 differs between the lytic and latent phases of Marek’s disease virus infection
JP2005523718A5 (enExample)
CN108096269A (zh) LncRNA的应用及应用其的药物
Ulasov et al. Oncolytic adenoviruses: a thorny path to glioma cure
NO330666B1 (no) Selektivt replikerende, rekombinant virusvektor, farmasoytisk formulering, fremgangsmate for dreping av en celle ex vivo med en reaksjonsveimangel, anvendelse av en selektivt replikerende viral vektor for fremstilling av et farmasoytisk preparat, samt fremgangsmate for fremstilling av en selektivt replikerende viral vektor.
Curtin et al. Turning the gene tap off; implications of regulating gene expression for cancer therapeutics
JP2007522797A5 (enExample)
CN1259106C (zh) 一种抗癌靶向基因病毒药物的制备方法
CN108018267A (zh) 一种靶向表观基因调控抗乙型肝炎病毒分子HBx1C及其应用
Meijer et al. Adenovirus type 12 E1A down regulates expression of a transgene under control of a major histocompatibility complex class I promoter: evidence for transcriptional control
Ding et al. Cytidine deamination and cccDNA degradation: A new approach for curing HBV?
JP2021505634A5 (enExample)
JP4402457B2 (ja) アデノウイルスｅ２後期プロモーターの制御のための、インビトロにおけるｙｂ−１の使用、及び、腫瘍の治療を目的とする医薬の製造のための当該使用を活用した核酸構築物の使用
JP2009535031A5 (enExample)